Hakim Mahammedi

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Eugene D. Kwon, Charles G. Drake, H. I. Scher et al. · The Lancet Oncology · 2014 · 1.5K citations · Full text

Urology, Oncology, Docetaxel Chemotherapy +9

Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial

Padmanee Sharma, Russell K. Pachynski, Vivek Narayan et al. · Cancer Cell · 2020 · 371 citations

Urology, Oncology, Nivolumab Plus Ipilimumab +8

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Michael J. Morris, Daniel Castellano, Ken Herrmann et al. · The Lancet · 2024 · 189 citations · Full text

Urology, Oncology, Genitourinary Cancer +8

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial

Sumanta K. Pal, Laurence Albigès, Piotr Tomczak et al. · The Lancet · 2023 · 173 citations · Full text

Urology, Genitourinary Cancer, Medicine +7

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors

Karim Fizazi, Charles G. Drake, Tomasz M. Beer et al. · European Urology · 2020 · 163 citations · Full text

Urology, Health Sciences, Medicine +8